Eli Lilly (NYSE: LLY) announced that preclinical data for agents targeting Nectin-4, KRAS G12D, and BRM will be presented at the American Association for Cancer Research, AACR), Annual Meeting, taking place April 5-10 in San Diego. The presentations will include new preclinical data for a fully human monoclonal anti-Nectin-4 antibody conjugated to a novel topoisomerase I inhibitor and a highly potent and orally administered inhibitor of KRAS G12D that is selective against wild-type KRAS. In addition, preclinical data on a potent and selective BRM inhibitor for the treatment of BRG1 mutated cancers will be presented in collaboration with Foghorn Therapeutics (FHTX). Investigational New Drug applications are planned for all three programs in 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on FHTX:
- Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909
- Is FHTX a Buy, Before Earnings?
- Foghorn’s FHD-909 Advances to Clinical Trials with Eli Lilly
- Foghorn Therapeutics Releases New Investor Presentation
- Foghorn Therapeutics says Lilly selects FHD-909 for clinical development
